Approved drugs for third-line use (meaning after two other drugs have been tried) in triple negative breast cancer only increase survival by 10% to 15%.
And yet here, Audiard paints a magnificently raw portrait, not only of survival, but of that most precious of human qualities -- the capacity to thrive, adapt and ultimately to transcend.